Craig Hopkinson, EVP of R&D and Chief Medical Officer at Alkermes plc ($ALKS), sold about $1.6 million worth of company shares in nine open market transactions over the last year. His most recent sale occurred on March 2, 2026. These sales rank 3,891st among over 11,678 insiders in our database, where the average is about $8.6 million across roughly 6.4 transactions. He made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 1, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 5000 | $0.00 | 16,356.0000 | 168,510,000 | 23.41% | 0.00% |
| April 1, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 5000 | $19.34 | 94,389.0000 | 168,510,000 | 5.59% | 0.00% |
| April 1, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 9000 | $35.51 | 85,389.0000 | 168,510,000 | 9.54% | 0.01% |
| March 2, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 9000 | $29.72 | 89,389.0000 | 168,510,000 | 9.15% | 0.01% |
| March 2, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 5000 | $0.00 | 21,356.0000 | 168,510,000 | 18.97% | 0.00% |
| March 2, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Employee Stock Option (Right to Buy) | 83037 | $0.00 | 83,037.0000 | 168,510,000 | 9999.99% | 0.05% |
| March 2, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Restricted Stock Unit Award | 38568 | $0.00 | 38,568.0000 | 168,510,000 | 9999.99% | 0.02% |
| March 2, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 5000 | $19.34 | 98,389.0000 | 168,510,000 | 5.35% | 0.00% |
| Feb. 26, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 6866 | $0.00 | 96,438.0000 | 168,510,000 | 7.67% | 0.00% |
| Feb. 26, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3049 | $30.73 | 93,389.0000 | 168,510,000 | 3.16% | 0.00% |
| Feb. 26, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 6866 | $0.00 | 13,732.0000 | 168,510,000 | 33.33% | 0.00% |
| Feb. 23, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3414 | $32.19 | 89,572.0000 | 168,510,000 | 3.67% | 0.00% |
| Feb. 23, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 7689 | $0.00 | 7,690.0000 | 168,510,000 | 50.00% | 0.00% |
| Feb. 23, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 7689 | $0.00 | 92,986.0000 | 168,510,000 | 9.01% | 0.00% |
| Feb. 18, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3504 | $32.02 | 81,031.0000 | 168,510,000 | 4.15% | 0.00% |
| Feb. 19, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3407 | $32.00 | 85,297.0000 | 168,510,000 | 3.84% | 0.00% |
| Feb. 18, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 8897 | $0.00 | 0.0000 | 168,510,000 | 100.00% | 0.01% |
| Feb. 19, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 7673 | $0.00 | 23,019.0000 | 168,510,000 | 25.00% | 0.00% |
| Feb. 18, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 8897 | $0.00 | 84,535.0000 | 168,510,000 | 11.76% | 0.01% |
| Feb. 19, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 7673 | $0.00 | 88,704.0000 | 168,510,000 | 9.47% | 0.00% |
| Feb. 5, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Ordinary Shares | 25352 | $0.00 | 83,092.0000 | 168,510,000 | 43.91% | 0.02% |
| Feb. 5, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 7454 | $33.55 | 75,638.0000 | 168,510,000 | 8.97% | 0.00% |
| Feb. 2, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 5000 | $0.00 | 26,356.0000 | 168,510,000 | 15.95% | 0.00% |
| Feb. 2, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 5000 | $19.34 | 66,740.0000 | 168,510,000 | 8.10% | 0.00% |
| Feb. 2, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 5000 | $34.24 | 61,740.0000 | 168,510,000 | 7.49% | 0.00% |
| Feb. 2, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 4000 | $33.54 | 57,740.0000 | 168,510,000 | 6.48% | 0.00% |
| Jan. 8, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 5000 | $0.00 | 31,356.0000 | 168,510,000 | 13.75% | 0.00% |
| Jan. 8, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 5000 | $30.00 | 61,740.0000 | 168,510,000 | 7.49% | 0.00% |
| Jan. 8, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 5000 | $19.34 | 66,740.0000 | 168,510,000 | 8.10% | 0.00% |
| Jan. 2, 2026 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 4000 | $28.00 | 61,740.0000 | 168,510,000 | 6.08% | 0.00% |
| Dec. 3, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 3748 | $30.00 | 65,740.0000 | 168,510,000 | 5.39% | 0.00% |
| Dec. 3, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 3748 | $0.00 | 36,356.0000 | 168,510,000 | 9.35% | 0.00% |
| Dec. 3, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 3748 | $19.34 | 69,488.0000 | 168,510,000 | 5.70% | 0.00% |
| Dec. 1, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 4000 | $29.30 | 65,740.0000 | 168,510,000 | 5.74% | 0.00% |
| Nov. 3, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 5000 | $19.34 | 78,740.0000 | 168,510,000 | 6.78% | 0.00% |
| Nov. 3, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 9000 | $30.38 | 69,740.0000 | 168,510,000 | 11.43% | 0.01% |
| Nov. 3, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 5000 | $0.00 | 40,104.0000 | 168,510,000 | 11.09% | 0.00% |
| Oct. 15, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 9000 | $31.53 | 73,740.0000 | 168,510,000 | 10.88% | 0.01% |
| Oct. 15, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 5000 | $19.34 | 82,740.0000 | 168,510,000 | 6.43% | 0.00% |
| Oct. 15, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 5000 | $0.00 | 45,104.0000 | 168,510,000 | 9.98% | 0.00% |
| Feb. 26, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3049 | $34.80 | 77,740.0000 | 169,198,000 | 3.77% | 0.00% |
| Feb. 26, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 6866 | $0.00 | 80,789.0000 | 169,198,000 | 9.29% | 0.00% |
| Feb. 26, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 6866 | $0.00 | 20,598.0000 | 169,198,000 | 25.00% | 0.00% |
| Feb. 22, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 12279 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.01% |
| Feb. 23, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3414 | $35.32 | 73,923.0000 | 169,198,000 | 4.41% | 0.00% |
| Feb. 23, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 7689 | $0.00 | 77,337.0000 | 169,198,000 | 11.04% | 0.00% |
| Feb. 22, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 5452 | $35.32 | 69,648.0000 | 169,198,000 | 7.26% | 0.00% |
| Feb. 22, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 12279 | $0.00 | 75,100.0000 | 169,198,000 | 19.55% | 0.01% |
| Feb. 23, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 7689 | $0.00 | 15,379.0000 | 169,198,000 | 33.33% | 0.00% |
| Feb. 19, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Restricted Stock Unit Award | 30692 | $0.00 | 30,692.0000 | 169,198,000 | 9999.99% | 0.02% |
| Feb. 18, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 8896 | $0.00 | 8,897.0000 | 169,198,000 | 50.00% | 0.01% |
| Feb. 18, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3950 | $35.90 | 62,821.0000 | 169,198,000 | 5.92% | 0.00% |
| Feb. 18, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 8896 | $0.00 | 66,771.0000 | 169,198,000 | 15.37% | 0.01% |
| Feb. 19, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Employee Stock Option (Right to Buy) | 63991 | $0.00 | 63,991.0000 | 169,198,000 | 9999.99% | 0.04% |
| Feb. 12, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 171813 | $32.69 | 90,983.0000 | 169,198,000 | 65.38% | 0.10% |
| Feb. 12, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 87566 | $20.03 | 151,166.0000 | 169,198,000 | 137.68% | 0.05% |
| Feb. 12, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 111630 | $19.34 | 262,796.0000 | 169,198,000 | 73.85% | 0.07% |
| Feb. 12, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 33108 | $33.27 | 57,875.0000 | 169,198,000 | 36.39% | 0.02% |
| Feb. 13, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 108833 | $31.93 | 166,708.0000 | 169,198,000 | 188.05% | 0.06% |
| Feb. 13, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 35586 | $24.59 | 202,294.0000 | 169,198,000 | 21.35% | 0.02% |
| Feb. 13, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 35586 | $34.02 | 166,708.0000 | 169,198,000 | 17.59% | 0.02% |
| Feb. 13, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 108833 | $36.02 | 57,875.0000 | 169,198,000 | 65.28% | 0.06% |
| Feb. 12, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 87566 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.05% |
| Feb. 12, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 111630 | $0.00 | 50,104.0000 | 169,198,000 | 69.02% | 0.07% |
| Feb. 13, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 108833 | $0.00 | 0.0000 | 169,198,000 | 100.00% | 0.06% |
| Feb. 13, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 35586 | $0.00 | 71,172.0000 | 169,198,000 | 33.33% | 0.02% |
| Feb. 6, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 15083 | $31.39 | 63,600.0000 | 169,198,000 | 19.17% | 0.01% |
| Feb. 6, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Ordinary Shares | 34393 | $0.00 | 78,683.0000 | 169,198,000 | 77.65% | 0.02% |
| Jan. 30, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 23542 | $0.00 | 106,758.0000 | 169,198,000 | 18.07% | 0.01% |
| Jan. 30, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 29156 | $0.00 | 87,566.0000 | 169,198,000 | 24.98% | 0.02% |
| Jan. 30, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 26589 | $0.00 | 161,734.0000 | 169,198,000 | 14.12% | 0.02% |
| Jan. 30, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 18345 | $0.00 | 92,271.0000 | 169,198,000 | 16.58% | 0.01% |
| Jan. 30, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 29156 | $20.03 | 76,732.0000 | 169,198,000 | 61.28% | 0.02% |
| Jan. 30, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 26589 | $19.34 | 103,321.0000 | 169,198,000 | 34.65% | 0.02% |
| Jan. 30, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 23542 | $24.59 | 126,863.0000 | 169,198,000 | 22.79% | 0.01% |
| Jan. 30, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 18345 | $26.82 | 145,208.0000 | 169,198,000 | 14.46% | 0.01% |
| Jan. 30, 2025 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 100918 | $32.05 | 44,290.0000 | 169,198,000 | 69.50% | 0.06% |
| Dec. 9, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 12090 | $0.00 | 188,323.0000 | 170,196,000 | 6.03% | 0.01% |
| Dec. 9, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 12452 | $0.00 | 116,722.0000 | 170,196,000 | 9.64% | 0.01% |
| Dec. 9, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 61151 | $32.07 | 47,576.0000 | 170,196,000 | 56.24% | 0.04% |
| Dec. 9, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 12411 | $26.82 | 108,727.0000 | 170,196,000 | 12.89% | 0.01% |
| Dec. 9, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 12044 | $24.59 | 96,316.0000 | 170,196,000 | 14.29% | 0.01% |
| Dec. 9, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 12090 | $19.34 | 84,272.0000 | 170,196,000 | 16.75% | 0.01% |
| Dec. 9, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 12452 | $20.03 | 72,182.0000 | 170,196,000 | 20.85% | 0.01% |
| Dec. 9, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 12411 | $0.00 | 110,616.0000 | 170,196,000 | 10.09% | 0.01% |
| Dec. 9, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 12044 | $0.00 | 130,300.0000 | 170,196,000 | 8.46% | 0.01% |
| Dec. 5, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 9221 | $31.50 | 59,730.0000 | 170,196,000 | 13.37% | 0.01% |
| Dec. 4, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 14349 | $30.77 | 68,951.0000 | 170,196,000 | 17.23% | 0.01% |
| Nov. 11, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 58996 | $30.08 | 83,300.0000 | 170,196,000 | 41.46% | 0.03% |
| Nov. 11, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 43058 | $20.03 | 142,296.0000 | 170,196,000 | 43.39% | 0.03% |
| Nov. 11, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Employee Stock Option (Right to Buy) | 43058 | $0.00 | 129,174.0000 | 170,196,000 | 25.00% | 0.03% |
| Nov. 6, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | S | Ordinary Shares | 10471 | $29.53 | 99,238.0000 | 170,196,000 | 9.54% | 0.01% |
| Feb. 26, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Employee Stock Option (Right to Buy) | 111186 | $0.00 | 111,186.0000 | 169,730,000 | 9999.99% | 0.07% |
| Feb. 23, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3414 | $29.57 | 109,709.0000 | 169,730,000 | 3.02% | 0.00% |
| Feb. 23, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 7689 | $0.00 | 113,123.0000 | 169,730,000 | 7.29% | 0.00% |
| Feb. 26, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Restricted Stock Unit Award | 27464 | $0.00 | 27,464.0000 | 169,730,000 | 9999.99% | 0.02% |
| Feb. 23, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 7689 | $0.00 | 23,068.0000 | 169,730,000 | 25.00% | 0.00% |
| Feb. 22, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 12278 | $0.00 | 110,886.0000 | 169,730,000 | 12.45% | 0.01% |
| Feb. 22, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 12278 | $0.00 | 12,279.0000 | 169,730,000 | 50.00% | 0.01% |
| Feb. 22, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 5452 | $28.91 | 105,434.0000 | 169,730,000 | 4.92% | 0.00% |
| Feb. 20, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 10297 | $0.00 | 0.0000 | 169,730,000 | 100.00% | 0.01% |
| Feb. 18, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 8897 | $0.00 | 96,834.0000 | 169,730,000 | 10.12% | 0.01% |
| Feb. 20, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 10297 | $0.00 | 103,180.0000 | 169,730,000 | 11.09% | 0.01% |
| Feb. 18, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3951 | $32.18 | 92,883.0000 | 169,730,000 | 4.08% | 0.00% |
| Feb. 20, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 4572 | $30.39 | 98,608.0000 | 169,730,000 | 4.43% | 0.00% |
| Feb. 18, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 8897 | $0.00 | 17,793.0000 | 169,730,000 | 33.33% | 0.01% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Restricted Stock Unit Award | 481 | $0.00 | 24,557.0000 | 163,742,000 | 2.00% | 0.00% |
| Feb. 8, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 15280 | $26.77 | 87,937.0000 | 169,730,000 | 14.80% | 0.01% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Employee Stock Option (Right to Buy) | 1599 | $58.40 | 81,599.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Employee Stock Option (Right to Buy) | 1089 | $65.94 | 55,589.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Employee Stock Option (Right to Buy) | 2133 | $31.93 | 108,833.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Employee Stock Option (Right to Buy) | 3376 | $20.03 | 172,232.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Restricted Stock Unit Award | 201 | $0.00 | 10,297.0000 | 163,742,000 | 1.99% | 0.00% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Employee Stock Option (Right to Buy) | 3929 | $19.34 | 200,413.0000 | 163,742,000 | 2.00% | 0.00% |
| Feb. 8, 2024 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Ordinary Shares | 46658 | $0.00 | 103,217.0000 | 169,730,000 | 82.49% | 0.03% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Employee Stock Option (Right to Buy) | 2790 | $24.59 | 142,344.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Restricted Stock Unit Award | 523 | $0.00 | 26,690.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Employee Stock Option (Right to Buy) | 2412 | $26.82 | 123,027.0000 | 163,742,000 | 2.00% | 0.00% |
| Nov. 17, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | J | Restricted Stock Unit Award | 603 | $0.00 | 30,757.0000 | 163,742,000 | 2.00% | 0.00% |
| Feb. 23, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Restricted Stock Unit Award | 30154 | $0.00 | 30,154.0000 | 163,742,000 | 9999.99% | 0.02% |
| Feb. 23, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Employee Stock Option (Right to Buy) | 120615 | $0.00 | 120,615.0000 | 163,742,000 | 9999.99% | 0.07% |
| Feb. 22, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 12038 | $0.00 | 24,076.0000 | 163,742,000 | 33.33% | 0.01% |
| Feb. 22, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 5345 | $27.77 | 56,559.0000 | 163,742,000 | 8.63% | 0.00% |
| Feb. 22, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 12038 | $0.00 | 61,904.0000 | 163,742,000 | 24.14% | 0.01% |
| Feb. 20, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 6526 | $28.07 | 46,044.0000 | 163,742,000 | 12.41% | 0.00% |
| Feb. 20, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | A | Ordinary Shares | 22195 | $0.00 | 52,570.0000 | 163,742,000 | 73.07% | 0.01% |
| Feb. 20, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3780 | $28.07 | 30,375.0000 | 163,742,000 | 11.07% | 0.00% |
| Feb. 21, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 6875 | $0.00 | 0.0000 | 163,742,000 | 100.00% | 0.00% |
| Feb. 18, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 2656 | $28.07 | 24,060.0000 | 163,742,000 | 9.94% | 0.00% |
| Feb. 18, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 8722 | $0.00 | 26,716.0000 | 163,742,000 | 48.47% | 0.01% |
| Feb. 20, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 10095 | $0.00 | 34,155.0000 | 163,742,000 | 41.96% | 0.01% |
| Feb. 20, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 10095 | $0.00 | 10,096.0000 | 163,742,000 | 50.00% | 0.01% |
| Feb. 18, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Restricted Stock Unit Award | 8722 | $0.00 | 26,167.0000 | 163,742,000 | 25.00% | 0.01% |
| Feb. 21, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | F | Ordinary Shares | 3053 | $27.77 | 49,866.0000 | 163,742,000 | 5.77% | 0.00% |
| Feb. 21, 2023 | Alkermes plc. | $ALKS | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | M | Ordinary Shares | 6875 | $0.00 | 52,919.0000 | 163,742,000 | 14.93% | 0.00% |